1. Home
  2. TENX vs ATNM Comparison

TENX vs ATNM Comparison

Compare TENX & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$15.54

Market Cap

56.2M

Sector

Health Care

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.34

Market Cap

45.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
ATNM
Founded
1967
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
45.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
ATNM
Price
$15.54
$1.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$22.50
$4.00
AVG Volume (30 Days)
301.2K
135.5K
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.11
52 Week Low
$4.63
$1.03
52 Week High
$18.38
$2.41

Technical Indicators

Market Signals
Indicator
TENX
ATNM
Relative Strength Index (RSI) 61.04 44.23
Support Level $11.06 $1.27
Resistance Level $16.84 $1.36
Average True Range (ATR) 1.61 0.07
MACD 0.08 -0.01
Stochastic Oscillator 60.86 29.00

Price Performance

Historical Comparison
TENX
ATNM

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: